Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the ...

This article explores how cancer biomarkers improve early detection, guide treatments and predict outcomes to transform ...

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

Background Chronic inflammation and elevated reactive oxygen species are key contributors to hepatocellular carcinoma (HCC) ...